Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven G Terra

Showing results (21-30 of 59) with videos related to

Pageof 6
Sort By:
Current Medical Research and Opinion|April 24, 2020
Efficacy and safety of ertugliflozin across racial groups in patients with type 2 diabetes mellitusJie Liu, Lisa Tarasenko, Annpey Pong, et al.
Diabetes, Obesity & Metabolism|December 5, 2019
Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitusJie Liu, Shrita Patel, Nilo B Cater, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 27, 2015
Pharmacokinetics and Disposition of the Thiouracil Derivative PF-06282999, an Orally Bioavailable, Irreversible Inactivator of Myeloperoxidase Enzyme, Across Animals and HumansJennifer Q Dong, Manthena V Varma, Angela Wolford, et al.
Current Medical Research and Opinion|April 24, 2020
Efficacy and safety of ertugliflozin in Hispanic/Latino patients with type 2 diabetes mellitusJie Liu, Lisa Tarasenko, Annpey Pong, et al.
Diabetes, Obesity & Metabolism|September 1, 2017
Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET)Julio Rosenstock, Juan Frias, Dénes Páll, et al.
Drugs in R&D|July 1, 2024
A Randomized, Open-Label, Phase I, Single-Dose Study of Antisense Oligonucleotide, Vupanorsen, in Chinese Adults with Elevated TriglyceridesXiaojie Wu, Jicheng Yu, Beikang Ge, et al.
Diabetes & Vascular Disease Research|May 14, 2019
Efficacy of ertugliflozin in monotherapy or combination therapy in patients with type 2 diabetes: A pooled analysis of placebo-controlled studiesJie Liu, Lisa Tarasenko, Steven G Terra, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|January 10, 2018
Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized StudySam Miller, Tania Krumins, Haojin Zhou, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|November 22, 2017
Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized StudyGeorge Grunberger, Sarah Camp, Jeremy Johnson, et al.
Diabetes, Obesity & Metabolism|January 25, 2017
Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise aloneSteven G Terra, Kristen Focht, Melanie Davies, et al.
Pageof 6

Showing results (21-30 of 59) with videos related to

Sort By:
Pageof 6
Current Medical Research and Opinion|April 24, 2020
Efficacy and safety of ertugliflozin across racial groups in patients with type 2 diabetes mellitusJie Liu, Lisa Tarasenko, Annpey Pong, et al.
Diabetes, Obesity & Metabolism|December 5, 2019
Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitusJie Liu, Shrita Patel, Nilo B Cater, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 27, 2015
Pharmacokinetics and Disposition of the Thiouracil Derivative PF-06282999, an Orally Bioavailable, Irreversible Inactivator of Myeloperoxidase Enzyme, Across Animals and HumansJennifer Q Dong, Manthena V Varma, Angela Wolford, et al.
Current Medical Research and Opinion|April 24, 2020
Efficacy and safety of ertugliflozin in Hispanic/Latino patients with type 2 diabetes mellitusJie Liu, Lisa Tarasenko, Annpey Pong, et al.
Diabetes, Obesity & Metabolism|September 1, 2017
Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET)Julio Rosenstock, Juan Frias, Dénes Páll, et al.
Drugs in R&D|July 1, 2024
A Randomized, Open-Label, Phase I, Single-Dose Study of Antisense Oligonucleotide, Vupanorsen, in Chinese Adults with Elevated TriglyceridesXiaojie Wu, Jicheng Yu, Beikang Ge, et al.
Diabetes & Vascular Disease Research|May 14, 2019
Efficacy of ertugliflozin in monotherapy or combination therapy in patients with type 2 diabetes: A pooled analysis of placebo-controlled studiesJie Liu, Lisa Tarasenko, Steven G Terra, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|January 10, 2018
Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized StudySam Miller, Tania Krumins, Haojin Zhou, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|November 22, 2017
Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized StudyGeorge Grunberger, Sarah Camp, Jeremy Johnson, et al.
Diabetes, Obesity & Metabolism|January 25, 2017
Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise aloneSteven G Terra, Kristen Focht, Melanie Davies, et al.
Pageof 6